How polyamines and hypusine affect type 1 diabetes
Polyamines and Hypusine in Type 1 Diabetes Pathogenesis
Looks at whether changing small molecules called polyamines and a related modification called hypusine in insulin-making beta cells can slow or prevent type 1 diabetes in people at risk or early in the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11236346 on NIH RePORTER |
What this research studies
This project focuses on small molecules called polyamines and a protein modification named hypusine that help control inflammation inside insulin-producing beta cells. Researchers will use advanced animal models, cell studies, and genetic tools to change the enzyme ornithine decarboxylase (ODC) in beta cells and alter hypusination of the translation factor eIF5A, tracking how those changes affect inflammation and autoimmune attack. They will also test whether dietary changes or drugs that modify polyamine levels influence diabetes progression in these models. The goal is to identify pathways that could be targeted in future human treatments to protect beta cells.
Who could benefit from this research
Good fit: People at high risk for type 1 diabetes (for example those with diabetes-related autoantibodies) or those with very recent-onset type 1 diabetes would be the most likely candidates for future clinical follow-up based on this work.
Not a fit: People with long-standing type 1 diabetes and little to no remaining beta cell function are unlikely to directly benefit from these early-stage findings.
Why it matters
Potential benefit: If successful, this work could point to new ways—including diet changes or drugs—to protect beta cells and slow or prevent type 1 diabetes.
How similar studies have performed: This approach is relatively new for type 1 diabetes: laboratory studies indicate polyamine and hypusine pathways influence inflammation, but human treatments based on these findings are not yet established.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Mirmira, Raghavendra G — University of Chicago
- Study coordinator: Mirmira, Raghavendra G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.